Applied DNA and strata reserve


Applied + DNA + Sciences% 2C + Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leading manufacturer of DNA polymerase chain reaction (PCR) and nucleic acid technologies, and Stratum Reservoir (Isotech) , LLC (“Isotech”), a division of Stratum Reservoir and a leader in the analysis of stable isotopes in the laboratory, a technique used for the analysis of fingerprints of natural organic compounds such as cotton, today announced to have entered into a Memorandum of Understanding (MoU). Under the terms of the MoU, Applied DNA will deploy Isotech’s isotope analysis (IA) as a confirmatory test for cotton genotyping, the process by which cotton DNA is used to determine the origin of fibers and cotton fabrics in a forensic manner. The memorandum of understanding should be followed by a final agreement between the companies.

The signing of the MoU follows the joint presentation of the initial data by the companies at an American Apparel and Footwear Association event that describes a methodology and results for the successful determination of the origin of fibers, Egyptian cotton yarns and fabrics using cotton genomics with AI assertion. The complementary use of AI to Applied DNA’s CertainT® platform for textile traceability allows for continuity of forensic data across a value chain based on natural fibers – from source to finished products – to ensure compliance with social standards (avoidance of products made with or forced labor) and environmental practices (sustainable, organic) aligned with regulatory and consumer expectations. According to the MoU, companies will support business development opportunities for cotton traceability. They will also continue to create and compile a global database of cotton, yarn and fabric samples from known sources in order to expand the application and utility of AI.

MeiLin Wan, Vice President of Textiles Sales at Applied DNA, said, “The use of AI complements our CertainT platform to deliver what we believe to be a premier, multi-layered approach to traceability and supply chain assurance across all natural fiber-based value chains. With CertainT, once origin is established, we provide certainty that we believe to be enduring and legal from source to shelf. The power of DNA is now increased with AI. ”

“Stable isotope analysis is a powerful tool that we have historically used in the oil and gas industry,” said Steven Pelphrey, director of Stratum Reservoir (Isotech), LLC. “Thanks to our collaboration with Applied DNA, we can now apply our proven technology and techniques more widely to the textile industry. This both enhances Applied DNA’s CertainT platform with an additional layer of geographic provenance and provides a solution unmatched in the market.

About Applied DNA Sciences

Applied DNA markets LinearDNA ™, its proprietary large-scale polymerase chain reaction (“PCR”) -based manufacturing platform that enables large-scale production of specific DNA sequences.

LinearDNA platform has utility in nucleic acid-based analysis in vitro diagnostics and market for the development and manufacture of drugs based on preclinical nucleic acids. The platform is used to fabricate DNA for clients as components of in vitro diagnostic tests and for the preclinical development of nucleic acid-based drugs in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (antiviral and anticancer), RNA therapies, based therapies evenly spaced short palindromic repeats (CRISPR); and gene therapy.

The LinearDNA platform also has non-organic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Major end markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.

Drawing on its deep expertise in nucleic acid-based technologies, the Company has also implemented safeCircle â„¢, a high-throughput turnkey solution for population-wide COVID-19 testing. safeCircle is designed to search for infection within defined populations or communities using high throughput testing methodologies that increase test efficiency and allow rapid turnaround times. The Company has also submitted an EUA authorization request for its LineaMT SARS-CoV-2 Mutation Panel, a test-based panel for the detection of certain genetic mutations in SARS-CoV-2.

Visit for more information. follow us on Twitter and LinkedIn. Join our mailing + list.

The Company’s common shares are listed on the NASDAQ under the symbol “APDN” and its publicly traded warrants are listed on OTC under the symbol “APPDW”.

Applied DNA is a member of the Russell Microcap® Index.

About Stratum Reservoir (Isotech), LLC

Isotech is a leading provider of laboratory services and equipment designed to provide scientific information to customers around the world, including specializing in high-precision analysis of carbon, hydrogen, gas, oxygen, nitrogen and sulfur isotopes for a variety of industries. Isotech is a member of the Stratum Reservoir group of companies, which operates rock and fluid analysis laboratories to enable the discovery and sustainable development of energy resources through applied geosciences.

For more information visit and follow us on LinkedIn.

Forward-looking statements

Statements made by Applied DNA in this press release may be “forward-looking” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act. 1995. Forward-looking statements describe the future plans, projections, strategies and expectations of Applied DNA, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, including Applied DNA’s ability to successfully enter into commercial contracts for the implementation. implementation of its CertainT® platform, the unknown ability to identify and commercialize a large number of geographic cotton biomarkers, the uncertainties inherent in research and development, and various other factors detailed from time to time in the reports and Applied DNA’s SEC files, including our annual report on Form 10-K filed on December 9, 2021, and other reports we file with the SEC, which are available at Applied DNA assumes no obligation to publicly update any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unforeseen events, except as otherwise required by law.

See the source version on


About Author

Comments are closed.